摘要
目的探讨腹膜透析治疗进入终末期肾脏病（ESRD）常染色体显性遗传性多囊肾病（ADPKD）患者的可行性及疗效。方法回顾性分析2003年10月至2011年2月期间在本院行腹膜透析治疗的11例ADPKD患者的临床资料。其中6例合并多囊肝，术前经影像学及家系调查确诊。11例均采用外科手术方法进行置管。观察术中术后并发症、导管相关性并发症、腹膜透析相关并发症、尿毒症症状改善情况、生存时间、退出透析或死亡等结局。结果11例手术均获成功，术中经过顺利，术后均未出现并发症。术后住院时间平均为12天。11例患者术后随访12～54个月，平均30个月。随访期间11例患者尿毒症症状均有改善，平均生存时间为31．6个月。1例因腹膜炎拔管重置，1例于透析14个月后转为血液透析治疗，1例因消化道出血死亡，1例因心力衰竭死亡。结论腹膜透析治疗ADPKD患者安全有效，ADPKD患者也可以选择腹膜透析作为初始的肾脏替代治疗．
Objectives To investigate the effect and feasibility of peritoneal dialysis （PD） on autosomal dominant polycystic kidney disease （ADPKD） patient with end - stage renal disease （ESRD）. Methods Clinical data of 11 autosomal dominant polycystic kidney disease （ADPKD） patients from October 2003 to Febrary 2011, ineluding 6 patients with polyeystie liver disease, diagnosed by iconography and family investigation ,were analyzed retrospectively. Peritoneal dialysis tube implanted by means of surgery. We observed intraoperative and postoperative complications,catheter - related complications , peritoneal dialysis - related complications, uremic symptoms improved,survival times,quit of dialysis or death,ect. Results All patients surgery successfully without intraoperative and postoperative complications. The mean average of hospital stay was 12 days. During the follow - up of 12 - 54 months , average survival time was 31.6 months. 1 patient with peritonitis, removal of peritoneal dialysis tube and re - implanted,1 patient undergoing hemodialysis after 14 months,2 patients dead. Conclusions ADPKD patients treated with PD safely and effectivlly,ADPKD patients can choose PD as the initial therapy of ESRD.
出处
《国际泌尿系统杂志》
2012年第4期459-461,共3页
International Journal of Urology and Nephrology
关键词
肾
多囊
常染色体显性
腹膜透析
Kidney,Polycystic,Autosomal Dominant
Peritoneal Dialysis
